Skip to content
Screener

Axogen AXGN Financing Cash Flow

Financing Cash Flow at other companies

Baxter International logo
Baxter InternationalBAX
-$11M+99.7%
Stryker logo
StrykerSYK
-$95M
IAR
Integra LifeSciencesIART
$8.3M-76.5%
LeMaitre Vascular logo
LeMaitre VascularLMAT
-$5.05M-82.8%
Artivion logo
ArtivionAORT
$152.39M+5,766%
Bioventus logo
BioventusBVS
-$23.43M-59.8%

Other financials

Income statement

See full
Revenue$69.7M+23.1%
Gross profit$50.7M+20.6%
Operating income-$2.2M-229%
Net income-$1.5M-362%
EPS (diluted)-$0.03-400%

Balance sheet

See full
Cash & equivalents$96.6M+271%
Total debt$20.1M-70.6%
Total equity$256.3M+128%
Total assets$304.9M+48.4%

Cash flow

See full
Operating cash flow$7.2M
CapEx$893.0K+23.7%
Free cash flow$6.3M

Valuation

See full
Market cap$2.38B+277%
Enterprise value$2.31B+242%
P/S9.5×+6.4×

Profitability

See full
Gross margin74.6%+0.3pp
Operating margin-5.1%
Net margin-13.4%-17.4pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18.2%-28.9pp
Debt / equity0.1×-0.5×
Current ratio6.6×+2.5×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Axogen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000805928-26-000094
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Payments of employee tax withholding on vested stock awards(9,273)
Cash paid for debt portion of financing lease obligations(9)(8)
Proceeds from exercise of stock options and ESPP stock purchases8,9223,547
Net cash provided by financing activities63,7023,539
Net increase (decrease) in cash and cash equivalents, and restricted cash57,024(7,518)
Cash and cash equivalents, and restricted cash, beginning of period39,54833,554
Cash and cash equivalents, and restricted cash, end of period$96,572$26,036
Supplemental disclosures of cash flow activity:

ITEM 1 — FINANCIAL STATEMENTS

FAQ

What is Axogen's financing cash flow?
Axogen (AXGN) reported financing cash flow of $4.2M in Q2 2026.
How has Axogen's financing cash flow changed year-over-year?
Axogen's financing cash flow increased by 262.7% year-over-year, from $1.16M to $4.2M.
What is the long-term trend for Axogen's financing cash flow?
Over 4 years (2021 to 2025), Axogen's financing cash flow has grown at a -15.4% compound annual growth rate (CAGR), from $20.45M to $10.5M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Axogen's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude